Real-Time Data... Are We Fixing The Right Bottleneck (Or Any For That Matter)?

By Derk Arts, MD PhD

The FDA’s recent pilot program for real-time data streaming aims to eliminate "dead time" in drug development, but the initiative has sparked a vital conversation among clinical data experts. While a cloud-based pipeline for regulatory surveillance signals a welcome shift toward modernization, the industry must ask if this solves the primary bottlenecks in research. True delays rarely stem from the final submission process; instead, they live within the labor-intensive cycle of patient recruitment, manual data transcription, and site-level administrative burdens.

For clinical trials to truly accelerate, the focus should shift toward systemic interoperability and the elimination of manual data entry. By enforcing strict data standards and breaking down vendor silos, we can reduce the 35% of trial inefficiencies caused by redundant data handling. This approach ensures that data managers receive clean, actionable insights from day one, ultimately freeing sites to focus on patient care rather than the crushing weight of administrative tasks.